Full-Time

Product Manager

Laboratory Test Execution

Confirmed live in the last 24 hours

Natera

Natera

1,001-5,000 employees

Genetic testing and diagnostics solutions provider

Compensation Overview

$100k - $160k/yr

Mid, Senior

Company Historically Provides H1B Sponsorship

Remote in USA

Remote USA

Category
Technical Product Management
Product Management
Product
Required Skills
Datadog
Agile
Product Management
SCRUM
Requirements
  • Bachelors in Computer Science, Life Science, or related field
  • 3-5 years of experience in Product Management
  • Experience with developing robust product requirement documentation for highly performing applications or backend systems
  • Strong technical skills: experienced with APIs, relational databases, monitoring tools (DataDog, Sumologic), workflow orchestration tools (Temporal), master data tools, documentation (Jama), cloud technologies and DMN rules engines.
  • Experience working in an Agile development environment building solutions from start to finish
  • Be able to break down large projects into granular milestones and track progress.
  • Experience in software development lifecycle process from build, software configuration, change control, and release and deployment activities.
  • Experience leading, influencing and partnering with remote engineering teams
  • Excellent verbal and written communication skills
  • Highly organized with ability to multi-task.
  • Proven ability to work and influence cross functional teams.
  • Effective in building strong rapport with key stakeholders.
  • Excellent communication, presentation, and relationship-building skills.
  • Ability to understand and describe technical complexities in a simplified way appropriate to different audiences.
Responsibilities
  • Craft and execute a comprehensive strategy for one or more components of the company’s laboratory test execution software suite that aligns with business objectives.
  • Create and maintain a technical product roadmap, prioritizing a feature backlog and enhancements that improve the processing of clinical orders and align with the overall strategic roadmap.
  • Lead strategic development initiatives to enhance our platform with reusable and extensible solutions.
  • Incorporate a focus on quality into product design, and work closely with development and software quality assurance teams on product and process improvements.
  • Act as a subject matter expert on our software products and create a shared understanding among business and technical teams.
  • Develop strong hands-on technical knowledge of Natera's software products and be able to aid in tasks ranging from configuration to testing and support.
  • Partner with engineering teams, product managers, architects and other stakeholders to ensure cross-alignment and successful delivery of product initiatives.
  • Drive projects from inception and discovery to delivery.
  • Responsible for the documentation of functional and technical requirements.
  • Responsible for user acceptance testing, software demonstrations and training.
  • Responsible for production support in partnership with staff from Engineering Production Support.
  • Participate in and facilitate scrum ceremonies.
Desired Qualifications
  • Bonus: familiarity with laboratory products, clinical testing processes, molecular biology workflows and bioinformatics pipelines.

Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their main technology is cell-free DNA (cfDNA) testing, which analyzes DNA fragments in the blood to detect minimal traces of cancer and assess organ health. Natera also offers tests for family planning and prenatal screening, including the Panorama NIPT, which has conducted over 2 million tests. The company generates revenue through testing services and kits, often reimbursed by insurance, and provides genetic counseling for personalized patient support.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Austin, Texas

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • Rising demand for personalized medicine supports Natera's genetic testing services.
  • The global NIPT market is expected to reach $7.3 billion by 2025.
  • Increased adoption of liquid biopsy tests aligns with Natera's cfDNA focus.

What critics are saying

  • Expansion into new Austin space could strain financial resources.
  • Increased competition from companies like Lantheus Holdings threatens market share.
  • HEROES trial for breast cancer may face regulatory hurdles or delays.

What makes Natera unique

  • Natera specializes in cell-free DNA testing for diverse medical applications.
  • Their Signatera test offers personalized ctDNA analysis for cancer patients.
  • Natera's Panorama NIPT has conducted over 2 million non-invasive prenatal tests.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible medical plans

Investment options

Time off

Workplace perks

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

5%
PRWeb
May 30th, 2025
The Melanoma Research Foundation To Host The Denver Miles For Melanoma 5K

The Melanoma Research Foundation (MRF) is thrilled to announce the next event in its annual Miles for Melanoma nationwide 5K program, bringing together local melanoma patients, supporters, care partners and thrivers. This year we will be hosting our annual Denver event on Saturday, June 14, 2025 at Sloan Lake Park at 7:30 AM MT. Opening Ceremonies will start at 8:30 AM MT and our race will kick off promptly at 9:00 AM MT. We are excited to share that Kyle Speller, PA Announcer for the Denver Nuggets, will be returning as our emcee on event day! We're also excited to welcome back local sponsor, Cara Mia Dermatology, who will be providing free on-site skin screenings—helping our community stay sun-safe while supporting a great cause.DENVER, May 29, 2025 /PRNewswire-PRWeb/ -- The Melanoma Research Foundation (MRF) is thrilled to announce the next event in its annual Miles for Melanoma nationwide 5K program, bringing together local melanoma patients, supporters, care partners and thrivers. This year we will be hosting our annual Denver event on Saturday, June 14, 2025 at Sloan Lake Park at 7:30 AM MT. Opening Ceremonies will start at 8:30 AM MT and our race will kick off promptly at 9:00 AM MT

Intelligence360
May 15th, 2025
Natera To Spend $9.9 Million To Occupy 30,000 Square Feet Of Space In Austin Texas.

Natera to spend $9.9 Million to occupy 30,000 square feet of space in Austin Texas. Natera to spend $9.9 Million to occupy 30,000 square feet of space in Austin Texas.Austin, Texas — According to state and local development sources, Natera plans to invest $9,900,000.00 to build out 30,000 square feet of new space in Austin. The company plans to occupy the new space at 13011A McCallen Pass in Austin, on or about January 1, 2026. According to the company website Natera is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, womens health, and organ health. Our aim is to make personalized genetic testing and diagnostics part of the standard of care to protect health and enable earlier and more targeted interventions that lead to longer, healthier lives. Where some set out to build a test, we set out to achieve a mission: change the management of disease worldwide by using DNA testing to proactively inform treatment

TXBN
Apr 24th, 2025
Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera(TM) Genome MRD Test

Natera announces broad clinical launch of ultra-sensitive signatera(tm) genome MRD test.

Slater Sentinel
Apr 3rd, 2025
DnB Asset Management AS Invests $235,000 in Natera, Inc. (NASDAQ:NTRA)

DnB Asset Management AS invests $235,000 in Natera, Inc. (NASDAQ:NTRA).

TXBN
Mar 25th, 2025
DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting

AUSTIN, Texas - (BUSINESS WIRE) - Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced that it will share results from the DEFINE-HT study in a late-breaking oral presentation at the International Society for Heart and Lung Transplantation (ISHLT) 45th Annual Meeting on April 29, 2025.